ライフサイエンスコーパス: hepatitis C

1 ct analysis" OR "cost benefit analysis" AND "hepatitis C".

2 revention of hepatocarcinogenesis in chronic hepatitis C.

3 by deadly RNA viruses such as influenza, and Hepatitis C.

4 US West and South have been most impacted by hepatitis C.

5 infections (eg, highest reported was 90% for hepatitis C, 67 [65%] of 103 individuals for hepatitis B

6 n some cases suggested to be associated with hepatitis C, although the evidence is very vague.

7 r racial groups show increasing rates due to hepatitis C and emergence of cirrhosis from non-alcoholi

8 tide prodrugs has led to important drugs for hepatitis C and HIV.

9 ition has been a target for the treatment of hepatitis C and other diseases, but the generation of po

10 sis persists even among participants without hepatitis C and/or HIV infection.

11 The corresponding odds ratio comparing hepatitis C antibodies (HCV Ab) (+) to HCV Ab (-) partic

12 Among patients coinfected with hepatitis C, aRR of mortality at 5 years was 91% lower a

13 Hepatitis C-associated liver cancer increased and consti

14 Hepatology practice has been dominated by hepatitis C but is now being overtaken by patients with

15 sease, nonalcoholic fatty liver disease, and hepatitis C, but no data are available for CHB.

16 Chronic hepatitis C can result in progressive liver disease and

17 In resource-rich countries, chronic hepatitis C (CHC) infection is associated with a sizeabl

18 ntation on serum fibrotic markers in chronic hepatitis C (CHC) patients.

19 patitis C virus (HCV) treatment, but chronic hepatitis C (CHC) remains a leading indication for liver

20 rtality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited.

21 th better clinical outcomes in patients with hepatitis C cirrhosis (n = 216), suggesting it may have

22 Hepatitis C clearance with directly acting antivirals (D

23 Chronic hepatitis B virus or hepatitis C co-infection was allowed.

24 ents if they were hepatitis B-co-infected or hepatitis C-co-infected, had new AIDS-defining condition

25 Despite effective treatment for chronic hepatitis C, deficiencies in diagnosis and access to car

26 Major developments in the management of hepatitis C have put elimination within reach, but sever

27 nt prevalence of HIV, hepatitis B (HBV), and hepatitis C (HCV) in people with severe mental illness,

28 Patients with chronic hepatitis C (HCV) infection have high prevalence of vita

29 Approximately three quarters of acute hepatitis C (HCV) infections evolve to a chronic state,

30 a quarter of individuals clear their primary hepatitis C (HCV) infections spontaneously, clearance (s

31 mage, especially in individuals with chronic hepatitis C (HCV); however, the impact of nonheavy use i

32 hronic liver diseases (CLDs), due to chronic hepatitis C; hepatitis B; nonalcoholic fatty liver disea

33 (HR, 15.9; 95% CI 1.8-145.2), and recipient hepatitis C (HR, 5.5; 95% CI 1.7-17.8) were significant

34 ation after DAA-based treatment of recurrent hepatitis C in an antibody against hepatitis B core anti

35 this Series paper, several issues related to hepatitis C in sub-Saharan Africa are addressed, includi

36 more cohesive manner to tackle the burden of hepatitis C in sub-Saharan Africa.

37 uture CHF events, particularly among HIV and hepatitis C infected people among whom cardiovascular di

38 Intravenous illicit drug use (IDU) and hepatitis C infection (HCV) commonly co-occur among HIV-

39 gest a secondary Mooren ulcer, but a chronic hepatitis C infection was detected.

40 itis and fibrosis progression during chronic hepatitis C infection, while contrasting results were re

41 ighly effective for the treatment of chronic hepatitis C infection.

42 le cell disease are at high risk for chronic hepatitis C infection.

43 livers explanted from patients with chronic hepatitis C infection.

44 atment regimens for both HIV co-infected and hepatitis C mono-infected patients are suggested.

45 The remedial response to hepatitis C must not neglect action on HRBs if it is to

46 ohort of non-cirrhotic patients with chronic hepatitis C or alcoholic liver disease (n = 1121), the T

47 ced hepatocellular carcinoma with or without hepatitis C or B (HCV or HBV) infection.

48 The treatment of chronic hepatitis C patients before they developed cirrhosis sho

49 terferon (IFN)-alpha treated chimpanzees and hepatitis C patients showed elevated APOBEC expression.

50 This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy

51 vational studies among compensated cirrhotic hepatitis C patients treated with interferon-containing

52 infected patients with deep vein thrombosis, hepatitis C, renal impairment, thyroid disease, and live

53 Treatment was targeted against hepatitis C (ribavirin and interferon) in addition to im

54 luation to Advance Screening and Testing for Hepatitis C study on HCV testing and costs among persons

55 kidney (DLK) transplant recipients from the Hepatitis C Therapeutic Registry and Research Network da

56 ses of acute symptomatic HEV infection after hepatitis C therapy in patients carrying anti-HEV immuno

57 and in this era of safer and more effective hepatitis C therapy, non-alcoholic fatty liver disease (

58 is an anti-viral molecule currently used in hepatitis C treatment.

59 Postpartum hepatitis C viral (HCV) load decline followed by spontan

60 icant cardiovascular disease, hepatitis B or hepatitis C viral infection, and a known bleeding disord

61 tocellular carcinoma and concomitant chronic hepatitis C viral infection.

62 tocellular carcinoma and concomitant chronic hepatitis C viral infection.

63 Chronic infections with hepatitis C virus (HCV) and HIV are highly prevalent in

64 Persons co-infected with hepatitis C virus (HCV) and HIV.

65 Patients co-infected with hepatitis C virus (HCV) and human immunodeficiency virus

66 steatosis (HS) is common in individuals with hepatitis C virus (HCV) and human immunodeficiency virus

67 Patients who are chronically infected with hepatitis C virus (HCV) and who do not have a sustained

68 [BPA], and patient solicitation), evaluated hepatitis C virus (HCV) antibody testing, diagnosis, and

69 afety and efficacy in treating patients with hepatitis C virus (HCV) awaiting liver transplant (LT).

70 Hepatitis C virus (HCV) causes chronic infections in at

71 Hepatitis C virus (HCV) causes mixed cryoglobulinemia (M

72 urrent standard of care for the treatment of hepatitis C virus (HCV) consists of interferon-free dire

73 Hepatitis C virus (HCV) cure rates have been similar in

74 Hepatitis C virus (HCV) displays a restricted host speci

75 we longitudinally sampled and sequenced the hepatitis C virus (HCV) envelope genome region (1,680 nu

76 ey population affected by the global HIV and hepatitis C virus (HCV) epidemics.

77 The Asia-Pacific region has disparate hepatitis C virus (HCV) epidemiology, with prevalence ra

78 Hepatitis C virus (HCV) exists as a lipoprotein-virus hy

79 cessary; however, PEP is not recommended for hepatitis C virus (HCV) exposures.

80 Patients chronically infected with hepatitis C virus (HCV) frequently develop mixed cryoglo

81 S5A, which is involved in replication of the hepatitis C virus (HCV) genome, presumably via membranou

82 r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) treatment in HI

83 n the United States for treatment of chronic hepatitis C virus (HCV) genotype 1 and 4 infections, as

84 The optimal retreatment strategy for hepatitis C virus (HCV) genotype 1-infected patients who

85 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) genotype 2 have high rates of re

86 ive samples, linearity, and performance with hepatitis C virus (HCV) genotypes were evaluated.

87 Current national hepatitis C virus (HCV) guidelines do not recommend the

88 Hepatitis C virus (HCV) has been shown to induce autopha

89 Hepatitis C virus (HCV) has dominated the field of hepat

90 is study examined the interactions among the hepatitis C virus (HCV) helicase and RLR helicases in li

91 miR-122, a pro-viral hepatitis C virus (HCV) host factor, binds and recruits

92 changes that occur upon prolonged passage of hepatitis C virus (HCV) in human hepatoma cells in an ex

93 tly-acting antivirals has been advocated for Hepatitis C Virus (HCV) in people who inject drugs (PWID

94 dynamics, and phenotypic diversification of hepatitis C virus (HCV) in the course of 200 passages in

95 Hepatitis C virus (HCV) infection affects over 130 milli

96 recommended regimens to treat patients with hepatitis C virus (HCV) infection after liver transplant

97 Treatment of chronic hepatitis C virus (HCV) infection after renal allograft

98 known of an epidemic of sexually transmitted hepatitis C virus (HCV) infection among human immunodefi

99 response (SVR) on outcomes of patients with hepatitis C virus (HCV) infection and compensated cirrho

100 lecaprevir and pibrentasvir in patients with hepatitis C virus (HCV) infection and compensated cirrho

101 The association between hepatitis C virus (HCV) infection and end-stage renal di

102 egimen for 12 weeks in patients with chronic hepatitis C virus (HCV) infection and stage 4-5 chronic

103 ociations between hepatitis B virus (HBV) or hepatitis C virus (HCV) infection and the development of

104 AIT cells in livers of patients with chronic hepatitis C virus (HCV) infection and their fate after a

105 Outcomes of hepatitis C virus (HCV) infection and treatment depend o

106 pment of drugs targeting the early stages of Hepatitis C virus (HCV) infection are hampered by the la

107 tive studies of the outcomes associated with hepatitis C virus (HCV) infection are rare and critical

108 have demonstrated that patients with chronic hepatitis C virus (HCV) infection associated HCC survive

109 nbiased genome-to-genome analysis in chronic hepatitis C virus (HCV) infection confirms the innate an

110 Whether chronic hepatitis C virus (HCV) infection decreases humoral and

111 with persistent and spontaneously resolving hepatitis C virus (HCV) infection during the acute phase

112 Hepatitis C virus (HCV) infection has been associated wi

113 In the United States, hepatitis C virus (HCV) infection has increased among yo

114 Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection has resulted in high r

115 acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection have demonstrated high

116 BACKGROUND & AIMS: Patients with chronic hepatitis C virus (HCV) infection have high rates of sus

117 of interferon and ribavirin to treat chronic hepatitis C virus (HCV) infection in kidney transplant r

118 ffective, and pan-genotypic regimen to treat hepatitis C virus (HCV) infection in patients coinfected

119 ng antiviral (DAA) medications, treatment of hepatitis C virus (HCV) infection in renal transplant re

120 asvir-sofosbuvir is effective at eradicating hepatitis C virus (HCV) infection in the general populat

121 In a previous study, we have shown that hepatitis C virus (HCV) infection induces epithelial-mes

122 Hepatitis C virus (HCV) infection is a common risk facto

123 BACKGROUND & AIMS: Chronic hepatitis C virus (HCV) infection is a major burden on i

124 Hepatitis C virus (HCV) infection is a major cause of li

125 Hepatitis C virus (HCV) infection is a major risk factor

126 Chronic hepatitis C virus (HCV) infection is associated with imp

127 Direct-acting antiviral treatment for hepatitis C virus (HCV) infection is costly and does not

128 efficacy of antiviral treatment for chronic hepatitis C virus (HCV) infection is determined by measu

129 Chronic hepatitis C virus (HCV) infection is more prevalent amon

130 Hepatitis C virus (HCV) infection is prevalent in the re

131 Hepatitis C virus (HCV) infection is the most common chr

132 immunodeficiency virus (HIV) and/or chronic hepatitis C virus (HCV) infection may be prescribed stat

133 s stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this associat

134 Whether chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infection promote NHL in HIV-inf

135 lines now recommend that patients with acute hepatitis C virus (HCV) infection should be treated with

136 e the relationships of hepatitis B (HBV) and hepatitis C virus (HCV) infection to age-related catarac

137 The predisposition of patients with Hepatitis C virus (HCV) infection to hepatocellular carc

138 atocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) infection treated with direct-ac

139 Historically, acute hepatitis C virus (HCV) infection was treated with short

140 People with hepatitis C virus (HCV) infection who have failed treatm

141 lete regimen for adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or w

142 Fibrosis is associated with chronic hepatitis C virus (HCV) infection, although the mechanis

143 ins are detected in 40%-60% of patients with hepatitis C virus (HCV) infection, and overt cryoglobuli

144 e the availability of curative treatment for hepatitis C virus (HCV) infection, because of cost, trea

145 ptor proteins AP1 and AP2, are essential for hepatitis C virus (HCV) infection, but the underlying me

146 For an efficient control of hepatitis C virus (HCV) infection, cytotoxic T cells (CT

147 ent of more effective drugs for treatment of hepatitis C virus (HCV) infection, there has been an inc

148 central role in the pathogenesis of chronic hepatitis C virus (HCV) infection.

149 esent the standard of care for patients with hepatitis C virus (HCV) infection.

150 agents (DAAs) are used increasingly to treat hepatitis C virus (HCV) infection.

151 have been approved for children with chronic hepatitis C virus (HCV) infection.

152 eradication to >90% in patients with chronic hepatitis C virus (HCV) infection.

153 patients with inherited blood disorders and hepatitis C virus (HCV) infection.

154 artments (EDs) seem to be able to detect new hepatitis C virus (HCV) infections at a high rate, but i

155 All patients with chronic hepatitis C virus (HCV) infections can and should be tre

156 Hepatitis C virus (HCV) is a single-stranded positive-se

157 Occult infection with hepatitis C virus (HCV) is defined as the presence of th

158 itious targets for global control of HIV and hepatitis C virus (HCV) is low levels of awareness of in

159 Viral load monitoring for hepatitis C virus (HCV) is necessary to diagnose infecti

160 Hepatitis C virus (HCV) is one of the leading causes of

161 Chronic infection with hepatitis C virus (HCV) is one of the main causes of hep

162 Hepatitis C virus (HCV) is unique among RNA viruses in i

163 ontributed to increased understanding of the hepatitis C virus (HCV) life cycle.

164 formed by glycoproteins E1 and E2 within the hepatitis C virus (HCV) lipid envelope is a potential va

165 Hepatitis C virus (HCV) nonstructural protein 5A (NS5A)

166 nt pan-genotype and macrocyclic inhibitor of hepatitis C virus (HCV) NS3/4A protease and was develope

167 BACKGROUND & AIMS: Inhibitors of the hepatitis C virus (HCV) NS5A protein are a key component

168 Hepatitis C virus (HCV) often causes persistent infectio

169 enib with alternative therapies according to hepatitis C virus (HCV) or hepatitis B virus (HBV) statu

170 rotein synthesis to directly incorporate the hepatitis C virus (HCV) p7 protein into supported lipid

171 s an urgent need for a vaccine to combat the hepatitis C virus (HCV) pandemic, and induction of broad

172 rd-of-care treatment of chronically infected hepatitis C virus (HCV) patients involves direct-acting

173 Hepatitis C virus (HCV) reactivation in patients receivi

174 to assess human immunodeficiency virus (HIV)/hepatitis C virus (HCV) real-world treatment outcomes.

175 pite recent advances in therapeutic options, hepatitis C virus (HCV) remains a severe global disease

176 Hepatitis C virus (HCV) remains the leading indication f

177 , exhibit potent inhibitory activity against hepatitis C virus (HCV) replication in genotype 1b Con 1

178 miR-122 is an important host factor for hepatitis C virus (HCV) replication.

179 Reliance on hepatitis C virus (HCV) replicon systems and protein-bas

180 Hepatitis C virus (HCV) requires multiple receptors for

181 polymerase that catalyzes replication of the hepatitis C virus (HCV) RNA genome and therefore is cent

182 The affordable and reliable detection of Hepatitis C Virus (HCV) RNA is a cornerstone in the mana

183 Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage

184 an electronic health record-based prompt on hepatitis C virus (HCV) screening rates in baby boomers

185 ntive Services Task Force recommend one-time hepatitis C virus (HCV) testing for persons born during

186 Highly effective hepatitis C virus (HCV) therapies have spurred a scale-u

187 There is a need for hepatitis C virus (HCV) therapies with excellent efficac

188 Rapid improvements in hepatitis C virus (HCV) therapy have led to the approval

189 out substitutions that mediate resistance of hepatitis C virus (HCV) to direct-acting antivirals (DAA

190 Cost-effectiveness analyses (CEAs) of hepatitis C virus (HCV) treatment strategies have become

191 ivirals (DAAs) have changed the landscape of hepatitis C virus (HCV) treatment, but chronic hepatitis

192 Eradication of hepatitis C virus (HCV) using direct-acting agents (DAA)

193 The association of hepatitis C virus (HCV) with non-Hodgkin's lymphoma (NHL

194 Hepatitis C virus (HCV)(+) donors represent an effective

195 ect drugs (PWID); and the prevalence of HIV, hepatitis C virus (HCV), and hepatitis B virus (HBV) amo

196 for detection of cirrhosis in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), NAFLD,

197 th decompensated cirrhosis (DC) secondary to hepatitis C virus (HCV), is associated with improved hep

198 RNA (+RNA) viruses including human pathogens hepatitis C virus (HCV), Severe acute respiratory syndro

199 with human immunodeficiency virus (HIV) and hepatitis C virus (HCV), we assessed fibrosis progressio

200 cohort of human immunodeficiency virus (HIV)/hepatitis C virus (HCV)-coinfected patients treated with

201 was cloned from T cells that expanded when a hepatitis C virus (HCV)-infected HLA-A2(-) individual re

202 k of chronic kidney disease (CKD) in chronic hepatitis C virus (HCV)-infected patients and the incide

203 Hepatitis C virus (HCV)-infected patients with chronic k

204 d high efficacy, safety, and tolerability in hepatitis C virus (HCV)-infected patients.

205 We prospectively evaluated 251 chronic hepatitis C virus (HCV)-infected subjects (31% human imm

206 Within hepatitis C virus (HCV)-like IRES elements, the sub-doma

207 Hepatitis C virus (HCV)-mediated chronic liver disease i

208 Identifying hepatitis C virus (HCV)-positive persons at high risk of

209 Guidelines recommend that patients with hepatitis C virus (HCV)-related liver disease be treated

210 The antiviral effects of hepatitis C virus (HCV)-specific CD8 T cells have been s

211 related to either hepatitis B virus (HBV) or hepatitis C virus (HCV).

212 on individuals are chronically infected with hepatitis C virus (HCV).

213 oRNA-122 is an important host factor for the hepatitis C virus (HCV).

214 cy virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).

215 1 million people worldwide are infected with hepatitis C virus (HCV).

216 IM-1 is important for efficient infection by hepatitis C virus (HCV).

217 l survival benefit for persons infected with hepatitis C virus (HCV).

218 mortality in patients with cirrhosis due to hepatitis C virus (HCV).

219 ly observed in individuals infected with the hepatitis C virus (HCV); however, the underlying molecul

220 A recombinant strain HCV1 (hepatitis C virus [HCV] genotype 1a) gpE1/gpE2 (E1E2) va

221 igh rates of sustained virological response (hepatitis C virus [HCV] RNA <15 IU/mL) at post-treatment

222 serostatus (+ or -: hepatitis B core [HBc], hepatitis C virus [HCV], Epstein-Barr virus [EBV], or cy

223 a performed well in patients with cACLD with hepatitis C virus and alcoholic and nonalcoholic steatoh

224 We demonstrate that, in sharp contrast to hepatitis C virus and human immunodeficiency virus patie

225 Although the related flaviviruses hepatitis C virus and human pegivirus (formerly named GB

226 or ultrasensitive and selective detection of hepatitis C virus core antigen (HCV) have been investiga

227 substratum to load antibody for detection of hepatitis C virus core antigen.

228 MC647055/ritonavir + JNJ-56914845 in chronic hepatitis C virus genotype (GT)1-infected treatment-naiv

229 6 weeks or less among patients with chronic hepatitis C virus genotype 1 infection.

230 rated and effective, particularly those with hepatitis C virus genotype 1 or 2 infection.

231 highly effective in adolescents with chronic hepatitis C virus genotype 2 or 3 infection.

232 and ribavirin in adolescents aged 12-17 with hepatitis C virus genotype 2 or 3.

233 Patients with hepatitis C virus genotype 3 infection with prior treatm

234 caprevir/pibrentasvir (G/P) in patients with hepatitis C virus genotype 3 infection with prior treatm

235 or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients a

236 n (54.1%, P = 0.001), had lower incidence of hepatitis C virus infection (4.9%, P = 0.001) and longer

237 old-especially those born in the peak era of hepatitis C virus infection and among whites/Caucasians.

238 called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such a

239 Children with chronic hepatitis C virus infection have limited treatment optio

240 antiviral drugs for the treatment of chronic hepatitis C virus infection have reduced mortality and t

241 s after DAA therapy in patients with chronic hepatitis C virus infection in the context of the immune

242 Chronic hepatitis C virus infection is associated with significa

243 Chronic hepatitis C virus infection is well-recognized as a comm

244 report a case series of three patients with hepatitis C virus infection who all presented with sever

245 djusted for age, race or ethnicity, smoking, hepatitis C virus infection, alcohol use disorders, drug

246 and well tolerated in patients with chronic hepatitis C virus infection, including those with compen

247 ) to interferon-based treatments for chronic hepatitis C virus infection, whereas Asian race was asso

248 revolutionized care of patients with chronic hepatitis C virus infection.

249 iral cytokine, are also less likely to clear hepatitis C virus infection.

250 us infection; 29.1% (95% CI: 23.6-34.5%) for hepatitis C virus infection; 33.9% (95% CI: 24.3-43.5%)

251 through the control of hepatitis B virus and hepatitis C virus infections by vaccination and treatmen

252 epatitis, especially chronic hepatitis B and hepatitis C virus infections.

253 ture-based design of HCV vaccines.IMPORTANCE Hepatitis C virus is a leading cause of liver disease an

254 lization of replication complexes.IMPORTANCE Hepatitis C virus is an important human pathogen.

255 stimulation during persistent infection with hepatitis C virus is associated with continuous activati

256 Hepatitis C virus is capable of establishing a lifelong

257 listed women differed in age (58 vs 57), non-hepatitis C virus listing diagnoses (69% vs 56%), hepati

258 29382 young persons currently infected with hepatitis C virus lived >10 miles from a syringe service

259 avage of four novel substrate motifs for the hepatitis C virus NS3/4 protease using an in vivo assay.

260 We conducted a retrospective cohort study of hepatitis C virus patients who were treated with DAA in

261 s to those of the initiation complex for the hepatitis C virus polymerase.

262 th cold ischemic time >12 hours, livers from hepatitis C virus positive donors, livers from donation

263 The protease NS3/4A from hepatitis C virus redistributes the complexes RIG-I/MAVS

264 ssion, all from an active IVDU donor who was hepatitis C virus seronegative at time of donation, but

265 ify the transmission dynamics that drive the hepatitis C virus subtypes 4a (HCV4a) and 4d (HCV4d) epi

266 There were 3 cases of unexpected hepatitis C virus transmission, all from an active IVDU

267 nce of some countries not following the 2016 hepatitis C virus treatment guidelines by the European A

268 rejection (n = 2 KT, 4 LT) occurred, during hepatitis C virus treatment in 4 and after cessation of

269 Extending hepatitis C virus treatment to patients in any fibrosis

270 Hepatitis C virus was the leading cause of hepatocellula

271 ategy for patients chronically infected with hepatitis C virus who experience virologic failure after

272 dations on the care of patients with chronic hepatitis C virus who have achieved SVR.

273 ople have been estimated to be infected with hepatitis C virus, and many more are at risk for infecti

274 a from patients with AIH, hepatitis B virus, hepatitis C virus, and nonalcoholic steatohepatitis.

275 SV) 1 and 2, human immunodeficiency virus 1, hepatitis C virus, enterovirus 70, and variant Creutzfel

276 st a wide variety of viruses, including HIV, hepatitis C virus, hepatitis B virus, enterovirus 71, in

277 as well as profound antiviral effect against hepatitis C virus, human rhinovirus, and coxsackievirus

278 ood and tissue donors, persons infected with hepatitis C virus, persons with elevated alanine aminotr

279 involved in the assembly and release of the hepatitis C virus, was determined from proteins expresse

280 the setting of viral hepatitis, particularly hepatitis C virus, where sustained viral response has be

281 ral direct-acting antiviral drugs (DAAs) for hepatitis C virus, which have response rates of 95% or m

282 BACKGROUND & AIMS: Patients with hepatitis C virus-associated cirrhosis and clinical sign

283 enter prospective study of 226 patients with hepatitis C virus-associated cirrhosis and CSPH who had

284 AA) therapies are effective in patients with hepatitis C virus-induced cryoglobulinemia vasculitis (H

285 hepatitis B virus (HBV) has been reported in hepatitis C virus-infected individuals receiving direct-

286 We identified 21,095 hepatitis C virus-infected patients (11,029 [52%] white,

287 the PITER cohort (representative of Italian hepatitis C virus-infected patients in care).

288 ir (LDV/SOF) can be considered in genotype 1 hepatitis C virus-infected patients who are treatment-na

289 treatment policies in a real-life cohort of hepatitis C virus-infected policy 1, "universal," treat

290 his retrospective evaluation included 62,290 hepatitis C virus-infected veterans completing oral DAA

291 Indeed, increased SALL4 expression in hepatitis C virus-related HCCs correlated with demethyla

292 ceiving irrelevant T cells redirected toward hepatitis C virus-specific TCRs.

293 rictions for people co-infected with HIV and hepatitis C virus.

294 be avoided in black patients with genotype 1 hepatitis C virus.

295 further show that kinesin knockdown inhibits hepatitis-C virus replication in hepatocytes, likely bec

296 Hepatitis C viruses (HCV) encode a helicase enzyme that

297 ory and immunosuppressive medication against hepatitis C was the key reason for the good results in t

298 ination among patients in China with chronic hepatitis C who are not in treatment.

299 Hepatitis C will fall from 30% to 21%.

300 The causality of hepatitis C with respect to the pathogenesis of Mooren u